SunTrust Banks Begins Coverage on Alexion Pharmaceuticals (NASDAQ:ALXN)

SunTrust Banks began coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note published on Tuesday, 24/7 WallStreet reports. The firm issued a buy rating and a $125.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the company. Raymond James lifted their target price on Alexion Pharmaceuticals from $168.00 to $170.00 and gave the stock an outperform rating in a research report on Thursday, October 24th. Bank of America began coverage on Alexion Pharmaceuticals in a research report on Thursday, October 17th. They set a buy rating on the stock. Oppenheimer decreased their target price on Alexion Pharmaceuticals from $165.00 to $150.00 in a research report on Thursday, October 24th. BidaskClub raised Alexion Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, September 11th. Finally, Citigroup set a $150.00 target price on Alexion Pharmaceuticals and gave the stock a buy rating in a research report on Friday, August 30th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $157.11.

Shares of NASDAQ:ALXN traded up $2.48 during midday trading on Tuesday, hitting $108.37. 1,743,700 shares of the stock were exchanged, compared to its average volume of 1,678,802. Alexion Pharmaceuticals has a 52-week low of $92.56 and a 52-week high of $141.86. The company has a market capitalization of $23.71 billion, a PE ratio of 15.28, a P/E/G ratio of 1.02 and a beta of 1.65. The business’s fifty day simple moving average is $102.94 and its two-hundred day simple moving average is $115.01. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.45 and a current ratio of 3.98.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.32. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the business earned $2.02 earnings per share. The firm’s revenue for the quarter was up 23.0% compared to the same quarter last year. As a group, equities analysts anticipate that Alexion Pharmaceuticals will post 9.39 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALXN. Nuveen Asset Management LLC boosted its holdings in Alexion Pharmaceuticals by 57,650.8% during the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock valued at $476,393,000 after purchasing an additional 3,630,846 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Alexion Pharmaceuticals by 104.9% during the second quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after purchasing an additional 840,742 shares in the last quarter. Swedbank boosted its holdings in Alexion Pharmaceuticals by 95.5% during the second quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after purchasing an additional 698,096 shares in the last quarter. Prudential Financial Inc. boosted its holdings in Alexion Pharmaceuticals by 87.0% during the second quarter. Prudential Financial Inc. now owns 1,180,067 shares of the biopharmaceutical company’s stock valued at $154,565,000 after purchasing an additional 549,063 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Alexion Pharmaceuticals by 1.3% during the second quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after purchasing an additional 211,960 shares in the last quarter. 94.56% of the stock is currently owned by institutional investors.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: Why do companies issue monthly dividends?

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.